LE WE PMID CA
Arterial hypertension (BASKET)225Arterielle Hypertonie (allg)

20 HETE

Aldosterone (Hyperaldosteronism Aldosteronism)

Aliskiren

Aminopeptidase A

Amlodipine

Arterial hypertension (BASKET)

Autonomous nervous system (BASKET)

Baroreceptor (BASKET)

Baroreceptor (stimulation)

Baroreflex

Blood vessels (Physiology)

Blood vessels (Resistance artery)

Calcium (Physiology renal)

Cardiorenal syndrome

Cardiovascular risk

Chlorthalidone

CNS (Circumventricular organs)

CNS (Intracerebral bleeding)

CNS (Stroke BASKET)

Diabetes mellitus (Involvement heart and vessels)

Diabetes mellitus T2DM (Type2)

Dinucleoside polyphosphates

Diuretic agents (Thiazides)

Drug interaction check

Endogenous ouabain

Endothelial dysfunction

Epoxide hydrolase

Epoxyeicosatrienoic acid EET

ERSNA efferent renal sympathetic nervous activity

Eye (Diseases)

Eye (Retinopathy hypertensive)

G protein coupled receptor kinase4

GRK4

Heart (Echocardiography)

Heart (Electrocardiography)

Heme oxygenase

Hemodialysis (BASKET)

Hydrochlorothiazide

Indapamide

Ion channel (Sodium ENaC)

Ion channel (Sodium)

Ion channel (TRP Family)

Kidney (Anatomy)

Kidney (Chronic renal failure)

Kidney (Failure acute)

Kidney (Microcirculation)

Kidney (Tubulus)

Leptin

Liddle s syndrome

Lysophosphatidate

Mechanotransduction

Melatonin

Metabolic syndrome

NADPH oxidase

NCC

NCX1

Nephroangiosclerosis malignant

Nephrolithiasis

Nephropathy (hypertensive)

Nephroprotective renoprotective agents

NKCC1

NKCC2

Nucleus tractus solitarius

Oat3

Obesity (BASKET)

Oligomeganephronia

Olmesartan

Organum vasculosum laminae terminalis

Orthostatic hypertension

Osmosensor

OSR1

Puls wave analysis

RAAS (Local Kidney)

RAAS (Renin angiotensin system)

Receptor (PPAR)

Renal denervation therapeutic

RGS protein family

Sclerodermia

Sleep apnea (obstructive)

Sodium (Salt)

SPAK

Statin

Subfornical organ

Sympathetic nervous system

Systemic lupus erythematosus

Thioredoxin

Thrombophilia

Transporter (Organic molecules)

Transporter (Sodium and calcium)

Transporter (Sodium and chloride)

Transporter (Sodium potassium and chloride)

TRPM7

TRPV1

Vanilloids

WNK

WNK1

WNK2

WNK3

WNK4

1978  
1
Nonpharmacologic control of essential hypertension in man: a critical review of the experimental literature.
[356079] Psychosom Med 40(4): 294-320 (1978)
1978  
2
Relaxation methods and the control of blood pressure.
[356077] Psychosom Med 40(4): 273-5 (1978)
2001  
3
ABC of hypertension: The pathophysiology of hypertension.
[11302910] BMJ 322(7291): 912-6 (2001)
1965  
4
Hyperpiesis: high blood-pressure without evident cause: essential hypertension.
[5318057] Br Med J 2(5469): 1021-6 concl (1965)
1965  
5
Hyperpiesis; high blood-pressure without evident cause: essential hypertension.
[5318678] Br Med J 2(5468): 959-68 contd (1965)
2010  
6
Angiotensin receptor blockers for management of hypertension.
[20531060] South Med J 103(7): 669-73 (2010)
2010  
7
Angiotensin-receptor blockers for the management of hypertension: new insights, new challenges.
[20531050] South Med J 103(7): 599-600 (2010)
2009  
8
Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy.
[19834426] South Med J 102(10 Suppl): S1-S12 (2009)
2008  
9
Resistant hypertension: identifying causes and optimizing treatment regimens.
[18364619] South Med J 101(2): 166-73 (2008)
2007  
10
Rationale for combination therapy in hypertension management: focus on angiotensin receptor blockers and thiazide diuretics.
[17458399] South Med J 100(4): 386-92 (2007)
2001  
11
2001  
12
Hypertension. Medication update.
[11780675] South Med J 94(11): 1065-70 (2001)
2000  
13
Pitfalls in the diagnosis and management of systolic hypertension.
[10728509] South Med J 93(3): 256-9 (2000)
2000  
14
Controlling hypertension in the elderly.
[10787447] QJM 93(4): 203-5 (2000)
1999  
15
Management of hypertension in patients developing end-stage renal failure.
[10627872] QJM 92(9): 519-25 (1999)
2003  
16
Hypertension: a review of therapeutic options.
[12971591] Manag Care 12(8 Suppl Hypertension): 34-44 (2003)
1999  
17
Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment.
[10218745] Arch Intern Med 159(7): 670-4 (1999)
2004  
18
Baroreflex failure: a neglected type of secondary hypertension.
[15366697] Neth J Med 62(5): 151-5 (2004)
2003  
19
New developments in the treatment of hypertension: are some antihypertensives more equal than others?
[12918545] Neth J Med 61(5 Suppl): 13-8 (2003)
2009  
20
Beta-blockers for hypertension: are they going out of style?
[19726558] Cleve Clin J Med 76(9): 533-42 (2009)
2008  
21
What is the proper workup of a patient with hypertension?
[18788227] Cleve Clin J Med 75(9): 663-72 (2008)
2007  
22
A different approach to resistant hypertension.
[17569203] Cleve Clin J Med 74(6): 449-56 (2007)
1979  
23
Pathogenesis of hypertensive retinopathy: a review.
[399635] J R Soc Med 72(5): 362-5 (1979)
2007  
24
Rebuttal: Do beta-blockers have a role in treating hypertension? Yes.
[17872734] Can Fam Physician 53(5): 800-3 (2007)
2007  
25
Do beta-blockers have a role in treating hypertension? No.
[17872703] Can Fam Physician 53(4): 614-21 (2007)
2007  
26
Do beta-blockers have a role in treating hypertension? Yes.
[17872702] Can Fam Physician 53(4): 614-21 (2007)
1998  
27
Echocardiography for primary care evaluation of hypertension.
[9870123] Can Fam Physician 44(-): 2702-6 (1998)
2003  
28
Clinical review: the management of hypertensive crises.
[12974970] Crit Care 7(5): 374-84 (2003)
2003  
29
Hypertension in the critically ill patient.
[16573454] Crit Care Resusc 5(1): 24-42 (2003)
2000  
30
Diagnosis and treatment of hypertension in children and adolescents.
[10863171] Can J Cardiol 16(6): 801-11 (2000)
1996  
31
Resistant hypertension: an overview.
[8842136] Can J Cardiol 12(9): 822-8 (1996)
2003  
32
Calcium antagonists in patients with type 2 diabetes and hypertension.
[12847562] Cardiovasc Drug Rev 21(2): 105-18 (2003)
2010  
33
Is it time to target prehypertension.
[21050419] Cardiovasc Ther 28(6): 337-8 (2010)
2011  
34
5-hydroxtryptamine receptors in systemic hypertension: an arterial focus.
[20433685] Cardiovasc Ther 29(1): 54-67 (2011)
2009  
35
Hypertension in the very elderly: Brief review of management.
[19653187] Cardiol J 16(4): 379-85 (2009)
2008  
36
Hypertension and microvascular remodelling.
[18250145] Cardiovasc Res 78(2): 274-85 (2008)
2006  
37
Redox signaling in hypertension.
[16765337] Cardiovasc Res 71(2): 247-58 (2006)
2004  
38
Interactions between the sympathetic nervous system and the kidneys in arterial hypertension.
[14736540] Cardiovasc Res 61(2): 238-46 (2004)
2002  
39
2000  
40
The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy.
[10728317] Cardiovasc Res 45(1): 82-91 (2000)
1987  
41
The large studies in hypertension: what have they shown?
[3326632] Br J Clin Pharmacol 24 Suppl 1(-): 3S-14S (1987)
1986  
42
1986  
43
1980  
44
Pharmacology of centrally acting hypotensive drugs.
[6104975] Br J Clin Pharmacol 10 Suppl 1(-): 13S-20S (1980)
2005  
45
The vanilloid receptor and hypertension.
[15715923] Acta Pharmacol Sin 26(3): 286-94 (2005)
2007  
46
Case study: pearls in hypertension pharmacotherapy.
[17605506] J Manag Care Pharm 13(5 Suppl): S13-6 (2007)
2007  
47
Overview of physiology, vascular biology, and mechanisms of hypertension.
[17605504] J Manag Care Pharm 13(5 Suppl): S6-8 (2007)
2010  
48
Exforge (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact.
[20694060] Core Evid 4(): 1-11 (2010)
2000  
49
Clinical overview of antihypertensive classes--clinically relevant differences: myths or facts? Based on a presentation by Alan H. Gradman, MD.
[10977460] Am J Manag Care 6(4 Suppl): S197-210 (2000)
1979  
50
The hypertensive patient: 1. Is treatment beneficial?
[455174] Can Med Assoc J 120(11): 1319-20 (1979)
1979  
51
Membranes and bile formation. Composition of several mammalian biles and their membrane-damaging properties.
[35277] Biochem J 178(1): 201-8 (1979)
1975  
52
Aldosterone and renin in essential hypertension.
[1098756] Can Med Assoc J 113(5): 421-31 (1975)
1965  
53
NEWER DRUGS IN THE TREATMENT OF HYPERTENSION.
[14289140] Can Med Assoc J 92(-): 918-22 (1965)
2007  
54
Hypertensive crises: challenges and management.
[17565029] Chest 131(6): 1949-62 (2007)
2000  
55
The diagnosis and management of hypertensive crises.
[10893382] Chest 118(1): 214-27 (2000)
1988  
56
Calcium antagonists in the treatment of hypertension. An overview.
[3286142] Chest 93(6): 1251-3 (1988)
2008  
57
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
[18574054] Circulation 117(25): e510-26 (2008)
2008  
58
Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension.
[18490538] Circulation 117(20): 2706-15; discussion 2715 (2008)
2008  
59
Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.
[18490537] Circulation 117(20): 2691-704; discussion 2705 (2008)
2007  
60
Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.
[17502569] Circulation 115(21): 2761-88 (2007)
2006  
61
Preventing vascular events due to elevated blood pressure.
[16684871] Circulation 113(18): 2166-8 (2006)
2005  
62
Natural history of hypertension subtypes.
[15753224] Circulation 111(9): 1094-6 (2005)
2004  
63
Hypertensive therapy: Part II.
[15226224] Circulation 109(25): 3081-8 (2004)
2004  
64
2002  
65
Evaluation and treatment of patients with systemic hypertension.
[12034648] Circulation 105(21): 2458-61 (2002)
2000  
66
New issues in the treatment of isolated systolic hypertension.
[10973833] Circulation 102(10): 1079-81 (2000)
2000  
67
Essential hypertension : part II: treatment.
[10653838] Circulation 101(4): 446-53 (2000)
2000  
68
Essential hypertension. Part I: definition and etiology.
[10645931] Circulation 101(3): 329-35 (2000)
2005  
69
Management of hypertension in elderly diabetic patients.
[16415770] Diabetes Metab 31 Spec No 2(): 5S82-5S91 (2005)
2008  
70
Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials.
[18852183] Eur Heart J 29(21): 2669-80 (2008)
2007  
71
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
[17562668] Eur Heart J 28(12): 1462-536 (2007)
2000  
72
Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'?
[11032692] Eur Heart J 21(20): 1653-65 (2000)
1999  
73
Treatment with beta-blockers for the primary prevention of the cardiovascular complications of hypertension.
[10075137] Eur Heart J 20(1): 11-24 (1999)
2003  
74
Cardiac and vascular pathophysiology in hypertension.
[12923045] Heart 89(9): 1104-9 (2003)
2001  
75
Essential hypertension: the heart and hypertension.
[11559694] Heart 86(4): 467-75 (2001)
2008  
76
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.
[18391085] Hypertension 51(6): 1403-19 (2008)
2006  
77
Mechanisms of sympathetic activation in obesity-related hypertension.
[17000932] Hypertension 48(5): 787-96 (2006)
2006  
78
Have ALLHAT, ANBP2, ASCOT-BPLA, and so forth improved our knowledge about better hypertension care?
[16735646] Hypertension 48(1): 1-7 (2006)
2005  
79
Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention.
[16009786] Hypertension 46(2): 386-92 (2005)
2005  
80
Management of prehypertension.
[15897368] Hypertension 45(6): 1056-61 (2005)
2005  
81
Obesity-associated hypertension: new insights into mechanisms.
[15583075] Hypertension 45(1): 9-14 (2005)
1993  
82
1993 guidelines for the management of mild hypertension. Memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee.
[8349333] Hypertension 22(3): 392-403 (1993)
2006  
83
Thiazide diuretics in the treatment of hypertension: an update.
[16565243] J Am Soc Nephrol 17(4 Suppl 2): S25-9 (2006)
1998  
84
Malignant hypertension and hypertensive emergencies.
[9440098] J Am Soc Nephrol 9(1): 133-42 (1998)
2008  
85
Antihypertensive treatment and stroke prevention in patients with and without chronic kidney disease: a review of controlled trials.
[18587726] J Nephrol 21(3): 374-83 (2008)
2006  
86
Central arterial pressure and arterial pressure pulse: new views entering the second century after Korotkov.
[16901029] Mayo Clin Proc 81(8): 1057-68 (2006)
2006  
87
The role of combination therapy in the management of hypertension.
[16714336] Nephrol Dial Transplant 21(6): 1469-73 (2006)
1997  
88
Malignant hypertension: still a challenge.
[9306367] Nephrol Dial Transplant 12(9): 2019-23 (1997)
2004  
89
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.
[15286277] Pediatrics 114(2 Suppl 4th Report): 555-76 (2004)
2003  
90
Classification and definition of disorders causing hypertonia in childhood.
[12509602] Pediatrics 111(1): e89-97 (2003)
2004  
91
Use of diuretics in cardiovascular disease: (2) hypertension.
[15138316] Postgrad Med J 80(943): 271-6 (2004)
1993  
92
A risk-benefit analysis for the treatment of hypertension.
[8290406] Postgrad Med J 69(816): 764-74 (1993)
1993  
93
Noninvasive 24 hour ambulatory blood pressure monitoring: current status.
[8321789] Postgrad Med J 69(810): 255-67 (1993)
1993  
94
1991  
95
2005  
96
Blood pressure reduction for vascular risk: is there a price to be paid?
[15860749] Stroke 36(6): 1308-13 (2005)
2004  
97
Blood pressure and stroke: an overview of published reviews.
[14976329] Stroke 35(3): 776-85 (2004)
2003  
98
Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is the key.
[12702834] Stroke 34(5): 1333-4 (2003)
2003  
99
Blood pressure-lowering for secondary prevention of stroke: ACE inhibition is not the key.
[12702833] Stroke 34(5): 1334-5 (2003)
1991  
100
Management of mild hypertension. Selecting an antihypertensive regimen.
[2024512] West J Med 154(1): 78-87 (1991)
1984  
101
Malignant or accelerated hypertension.
[6372248] West J Med 140(4): 575-82 (1984)
1980  
102
Antihypertensive pharmacology.
[6992462] West J Med 132(5): 430-9 (1980)
1979  
103
Nontraditional problems of antihypertensive management.
[18748465] West J Med 131(3): 179-92 (1979)
2008  
104
Resistant hypertension: an overview of evaluation and treatment.
[19022154] J Am Coll Cardiol 52(22): 1749-57 (2008)
2007  
105
Hypertension in the young: preventing the evolution of disease versus prevention of clinical events.
[17719469] J Am Coll Cardiol 50(9): 840-2 (2007)
2005  
106
Home blood pressure measurement: a systematic review.
[16139119] J Am Coll Cardiol 46(5): 743-51 (2005)
2005  
107
Recent hypertension trials: implications and controversies.
[15766813] J Am Coll Cardiol 45(6): 813-27 (2005)
2001  
108
Pulse pressure--a review of mechanisms and clinical relevance.
[11263624] J Am Coll Cardiol 37(4): 975-84 (2001)
1996  
109
Primary renal abnormalities in hereditary hypertension.
[8872945] Kidney Int 50(3): 717-31 (1996)
2001  
110
Molecular mechanisms of human hypertension.
[11239411] Cell 104(4): 545-56 (2001)
2006  
111
Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.
[16754904] CMAJ 174(12): 1737-42 (2006)
2000  
112
Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 2: Beta-blockers.
[10934984] CMAJ 163(2): 188-92 (2000)
2000  
113
Choosing a first-line drug in the management of elevated blood pressure: what is the evidence? 1: Thiazide diuretics.
[10920733] CMAJ 163(1): 57-60 (2000)
1999  
114
Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?
[10420860] CMAJ 161(1): 25-32 (1999)
1993  
115
Integration of factors controlling vascular tone. Overview.
[8267212] Anesthesiology 79(6): 1368-80 (1993)
1977  
116
Psychological methods in treatment of hypertension: a review.
[328023] Br Heart J 39(6): 587-93 (1977)
1971  
117
What is hypertension? Recent studies on neurogenic hypertension.
[4929434] Br Heart J 33(-): Suppl:109-12 (1971)
2003  
118
Better blood pressure control: how to combine drugs.
[12574784] J Hum Hypertens 17(2): 81-6 (2003)
2000  
119
Hypertension and the prothrombotic state.
[11095159] J Hum Hypertens 14(10-11): 687-90 (2000)
2000  
120
Cerebral complications of hypertension.
[11095154] J Hum Hypertens 14(10-11): 605-16 (2000)
1999  
121
Clinical presentation and management of patients with uncontrolled, severe hypertension: results from a public teaching hospital.
[10333343] J Hum Hypertens 13(4): 249-55 (1999)
1998  
122
Isolated systolic hypertension: pathophysiology, consequences and therapeutic benefits.
[9783491] J Hum Hypertens 12(9): 621-6 (1998)
1998  
123
Secondary hypertension in the elderly.
[9783488] J Hum Hypertens 12(9): 603-6 (1998)
2007  
124
Recent update in the management of hypertension.
[18380058] Acta Med Indones 39(4): 186-91 (2007)
2010  
125
Pivotal role of the kidney in hypertension.
[20610969] Am J Med Sci 340(1): 30-2 (2010)
2007  
126
NKCC1 as a regulator of vascular tone and a novel target for antihypertensive therapeutics.
[17308011] Am J Physiol Heart Circ Physiol 292(5): H2035-6 (2007)
2008  
127
The beginning of a fantastic, unanswered question: is 5-HT involved in systemic hypertension?
[18775854] Am J Physiol Heart Circ Physiol 295(3): H915-H916 (2008)
2009  
128
A new piece in the hypertension puzzle: central blood pressure regulation by sex steroids.
[19801489] Am J Physiol Heart Circ Physiol 297(5): H1583-4 (2009)
2009  
129
Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension.
[19734358] Am J Physiol Heart Circ Physiol 297(5): H1567-75 (2009)
2010  
130
Endogenous cardiotonic steroids and salt-sensitive hypertension.
[20347967] Biochim Biophys Acta 1802(12): 1230-6 (2010)
2010  
131
Genetics of hypertension: from experimental animals to humans.
[20035862] Biochim Biophys Acta 1802(12): 1299-308 (2010)
2007  
132
2010  
133
The effects of biofeedback in diabetes and essential hypertension.
[20622080] Cleve Clin J Med 77 Suppl 3(-): S68-71 (2010)
2011  
134
Goal-directed antihypertensive therapy: lower may not always be better.
[21285345] Cleve Clin J Med 78(2): 123-33 (2011)
2009  
135
Beyond office sphygmomanometry: ways to better assess blood pressure.
[19884295] Cleve Clin J Med 76(11): 657-62 (2009)
2010  
136
Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.
[20921433] Hypertension 56(5): 780-800 (2010)
2010  
137
Morning surge in blood pressure and cardiovascular risk: evidence and perspectives.
[20937968] Hypertension 56(5): 765-73 (2010)
2010  
138
Salt and aldosterone: a concert of bad effects.
[20921423] Hypertension 56(5): 804-5 (2010)
2010  
139
DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension.
[20921424] Hypertension 56(5): 806-7 (2010)
2010  
140
Sympathetic nervous activation in essential hypertension: commonly neglected as a therapeutic target, usually ignored as a drug side effect.
[20368501] Hypertension 55(5): 1090-1 (2010)
2010  
141
Drug combinations in the treatment of hypertension: never-ending novelty.
[20479332] Hypertension 56(1): 22-3 (2010)
2010  
142
Strategies and goals for hypertension control in patients with diabetes mellitus.
[20497989] Hypertension 56(1): 24-5 (2010)
2010  
143
Sympathetic nervous system and blood pressure in humans: individualized patterns of regulation and their implications.
[20497993] Hypertension 56(1): 10-6 (2010)
2010  
144
Electrical carotid baroreceptor stimulation in resistant hypertension.
[20100993] Hypertension 55(3): 607-9 (2010)
2010  
145
Mineralocorticoid receptors, salt-sensitive hypertension, and metabolic syndrome.
[20176994] Hypertension 55(4): 813-8 (2010)
2010  
146
Implications of recently published trials of blood pressure-lowering drugs in hypertensive or high-risk patients.
[20212274] Hypertension 55(4): 819-31 (2010)
2010  
147
Unresolved issues in the management of hypertension.
[20215564] Hypertension 55(4): 832-4 (2010)
2008  
148
Transient receptor potential vanilloid type 1 receptors in hypertensive renal damage: a promising therapeutic target?
[18606896] Hypertension 52(2): 213-4 (2008)
2004  
149
Novel mechanisms responsible for postmenopausal hypertension.
[15023933] Hypertension 43(5): 918-23 (2004)
2004  
150
Hypertension and cyclooxygenase-2 inhibitors: target: the renal medulla.
[15314033] Hypertension 44(4): 396-7 (2004)
2004  
151
Alcohol-associated hypertension: when one drinks makes a difference.
[15492132] Hypertension 44(6): 805-6 (2004)
2009  
152
The pump, the exchanger, and endogenous ouabain: signaling mechanisms that link salt retention to hypertension.
[19104005] Hypertension 53(2): 291-8 (2009)
2009  
153
Mitochondrial dysfunction and mitochondrial-produced reactive oxygen species: new targets for neurogenic hypertension?
[19114641] Hypertension 53(2): 112-4 (2009)
2009  
154
Cardiovascular protection with antihypertensive drugs in dialysis patients: systematic review and meta-analysis.
[19273737] Hypertension 53(5): 860-6 (2009)
2007  
155
Treating resistant hypertension with a neglected old drug.
[17309945] Hypertension 49(4): 763-4 (2007)
2007  
156
Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials.
[17309949] Hypertension 49(4): 792-8 (2007)
2005  
157
Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.
[15809363] Hypertension 45(5): 880-6 (2005)
2005  
158
2009  
159
Postmenopausal hypertension: mechanisms and therapy.
[19470884] Hypertension 54(1): 11-8 (2009)
2009  
160
Mitochondrial Thioredoxin: novel regulator for NADPH oxidase and angiotensin II-induced hypertension.
[19506095] Hypertension 54(2): 224-5 (2009)
2009  
161
Assessment of sympathetic cardiovascular drive in human hypertension: achievements and perspectives.
[19720958] Hypertension 54(4): 690-7 (2009)
2005  
162
The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies.
[16103270] Hypertension 46(3): 463-8 (2005)
2005  
163
Neurogenic mechanisms and salt sensitivity.
[16230507] Hypertension 46(6): 1259-60 (2005)
2005  
164
Baroreflexes in hypertension: a mystery revisited.
[16216986] Hypertension 46(5): 1095-6 (2005)
2008  
165
A tale of two patients with Mendelian hypertension.
[18268135] Hypertension 51(3): 609-14 (2008)
2008  
166
Pathogenesis of elevated peripheral pulse pressure: some reflections and thinking forward.
[18071060] Hypertension 51(1): 33-6 (2008)
2008  
167
Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension?
[18086947] Hypertension 51(2): 168-71 (2008)
2008  
168
Update on the use of antihypertensive drugs in pregnancy.
[18259046] Hypertension 51(4): 960-9 (2008)
2008  
169
Aminopeptidase A: could it be a novel target for neurogenic hypertension?
[18362227] Hypertension 51(5): 1273-4 (2008)
2008  
170
G protein-coupled receptor kinase 4: role in blood pressure regulation.
[18347232] Hypertension 51(6): 1449-55 (2008)
2008  
171
Kidney in hypertension: guyton redux.
[18332286] Hypertension 51(4): 811-6 (2008)
2008  
172
Pediatric antihypertensive trial failures: analysis of end points and dose range.
[18332283] Hypertension 51(4): 834-40 (2008)
2008  
173
Kidney and circadian blood pressure rhythm.
[18316650] Hypertension 51(4): 827-8 (2008)
2005  
174
Vascular development, pulse pressure, and the mechanisms of hypertension.
[15911744] Hypertension 46(1): 205-9 (2005)
2009  
175
Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept.
[19822798] Hypertension 54(6): 1195-201 (2009)
2009  
176
Another major role for dietary sodium reduction: improving blood pressure control in patients with resistant hypertension.
[19620515] Hypertension 54(3): 444-6 (2009)
2010  
177
RGS2 proteins regulate blood pressure.
[20947628] J Am Soc Nephrol 21(11): 1809-10 (2010)
2004  
178
Overview: mechanisms of hypertension: cells, hormones, and the kidney.
[15284282] J Am Soc Nephrol 15(8): 1971-3 (2004)
2003  
179
Prevention of hypertension and its complications: theoretical basis and guidelines for treatment.
[12819310] J Am Soc Nephrol 14(7 Suppl 2): S92-8 (2003)
2005  
180
Prenatal programming of hypertension: lessons from experimental models.
[16049066] J Am Soc Nephrol 16(9): 2545-56 (2005)
2007  
181
Salt-sensitive hypertension--update on novel findings.
[17210585] Nephrol Dial Transplant 22(4): 992-5 (2007)
2010  
182
Hypertension in children and adolescents: epidemiology and natural history.
[19421783] Pediatr Nephrol 25(7): 1219-24 (2010)
2009  
183
At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension.
[18320238] Pediatr Nephrol 24(11): 2137-46 (2009)
2009  
184
Treatment of hypertension in children and adolescents.
[17690916] Pediatr Nephrol 24(10): 1939-49 (2009)
2009  
185
2010  
186
Neural set point for the control of arterial pressure: role of the nucleus tractus solitarius.
[20064256] Biomed Eng Online 9(-): 4 (2010)
2010  
187
The search for strategies to control hypertension.
[20823382] Circulation 122(12): 1141-3 (2010)
2003  
188
Morning surge in blood pressure.
[12642350] Circulation 107(10): 1347 (2003)
2005  
189
2011  
190
Mevalonate pathway is a novel target for hypertension.
[21532185] Circ J 75(6): 1318-9 (2011)
2011  
191
Transient receptor potential melastatin 7 (TRPM7) cation channels, magnesium and the vascular system in hypertension.
[21150127] Circ J 75(2): 237-45 (2011)
2010  
192
Sympathoinhibitory effects of atorvastatin in hypertension.
[21088328] Circ J 74(12): 2552-3 (2010)
2009  
193
Orthostatic hypertension: a measure of blood pressure variation for predicting cardiovascular risk.
[19430163] Circ J 73(6): 1002-7 (2009)
2003  
194
Intrauterine undernutrition--renal and vascular origin of hypertension.
[14613851] Cardiovasc Res 60(2): 228-34 (2003)
2008  
195
The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway.
[18843116] J Cell Sci 121(Pt 20): 3293-304 (2008)
2010  
196
Epithelial Na+ channel (ENaC), hormones, and hypertension.
[20460373] J Biol Chem 285(31): 23527-31 (2010)
2010  
197
Role of epithelial sodium channels and their regulators in hypertension.
[20624922] J Biol Chem 285(40): 30363-9 (2010)
2009  
198
Management of blood pressure for acute and recurrent stroke.
[19390077] Stroke 40(6): 2251-6 (2009)
2010  
199
2010  
200
High blood pressure in the pediatric age group.
[20635566] Rev Port Cardiol 29(3): 413-32 (2010)
2005  
201
Hypertension in children and adolescents.
[16335283] Rev Port Cardiol 24(9): 1091-4 (2005)
2008  
202
Some reflections on prehypertension.
[19280998] Rev Port Cardiol 27(12): 1583-9 (2008)
2008  
203
Malignant hypertension, severe hypertensive retinopathy and malignant nephroangiosclerosis.
[18551923] Rev Port Cardiol 27(3): 373-9 (2008)
2009  
204
2010  
205
Hyperosmotic activation of CNS sympathetic drive: implications for cardiovascular disease.
[20603334] J Physiol 588(Pt 18): 3375-84 (2010)
2006  
206
Topics on the Na+/Ca2+ exchanger: role of vascular NCX1 in salt-dependent hypertension.
[16960423] J Pharmacol Sci 102(1): 32-6 (2006)
2009  
207
Dinucleoside polyphosphates: strong endogenous agonists of the purinergic system.
[19563527] Br J Pharmacol 157(7): 1142-53 (2009)
2009  
208
Endothelium-dependent contractions and endothelial dysfunction in human hypertension.
[19630832] Br J Pharmacol 157(4): 527-36 (2009)
2004  
209
2005  
210
Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases.
[15788708] Physiol Rev 85(2): 679-715 (2005)
2009  
211
Physiological significance of heme oxygenase in hypertension.
[19027871] Int J Biochem Cell Biol 41(5): 1025-33 (2009)
2011  
212
Treatment strategies for resistant arterial hypertension.
[22114648] Dtsch Arztebl Int 108(43): 725-31 (2011)
2005  
213
Abnormalities of the resistance vasculature in hypertension: correction by vasodilator therapy.
[16415495] Pharmacol Rep 57 Suppl(-): 144-50 (2005)
2008  
214
Angiotensin II type 1 receptor blocker combined with hydrochlorothiazide for the treatment of hypertension.
[18591834] Intern Med 47(13): 1163-4 (2008)
2004  
215
Systolic hypertension in older persons.
[15339901] JAMA 292(9): 1074-80 (2004)
2004  
216
The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
[14968142] Can J Cardiol 20(1): 41-54 (2004)
2004  
217
The 2004 Canadian recommendations for the management of hypertension: Part III--Lifestyle modifications to prevent and control hypertension.
[14968143] Can J Cardiol 20(1): 55-9 (2004)
2004  
218
The 2004 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.
[14968141] Can J Cardiol 20(1): 31-40 (2004)
2003  
219
Potential role of lysophosphatidic acid in hypertension and atherosclerosis.
[14760444] Can J Cardiol 19(13): 1525-36 (2003)
2007  
220
Night-time blood pressure patterns and target organ damage: a review.
[17311119] Can J Cardiol 23(2): 132-8 (2007)
2007  
221
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 1- blood pressure measurement, diagnosis and assessment of risk.
[17534459] Can J Cardiol 23(7): 529-38 (2007)
2007  
222
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
[17534460] Can J Cardiol 23(7): 539-50 (2007)
2007  
223
More medications, fewer pills: combination medications for the treatment of hypertension.
[17534465] Can J Cardiol 23(7): 573-6 (2007)
2007  
224
Treatment of hypertension in patients with nondiabetic chronic kidney disease.
[17534470] Can J Cardiol 23(7): 595-601 (2007)
2007  
225
Musings regarding hypertension.
[17593584] Can J Cardiol 23(7): 603-4 (2007)
2009  
226
2009  
227
2009 Canadian Hypertension Education Program recommendations: the scientific summary--an annual update.
[19417857] Can J Cardiol 25(5): 271-7 (2009)
2009  
228
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk.
[19417858] Can J Cardiol 25(5): 279-86 (2009)
2009  
229
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy.
[19417859] Can J Cardiol 25(5): 287-98 (2009)
2009  
230
Hypertension in diabetes: a call to action.
[19417860] Can J Cardiol 25(5): 299-302 (2009)
2009  
231
Hypertension in dialysis and kidney transplant patients.
[19417862] Can J Cardiol 25(5): 309-14 (2009)
2008  
232
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.
[18548143] Can J Cardiol 24(6): 465-75 (2008)
2008  
233
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk.
[18548142] Can J Cardiol 24(6): 455-63 (2008)
2010  
234
Diagnostic modalities of the most common forms of secondary hypertension.
[21169184] Hellenic J Cardiol 51(6): 518-29 (2010)
2008  
235
Beta-blockers in the treatment of hypertension: latest data and opinions.
[18350781] Hellenic J Cardiol 49(1): 37-47 (2008)
2010  
236
Strategies for initial management of hypertension.
[21150005] Indian J Med Res 132(5): 531-42 (2010)
2010  
237
Aliskiren and valsartan combination therapy for the management of hypertension.
[20859542] Vasc Health Risk Manag 6(-): 711-22 (2010)
2011  
238
Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials.
[21966222] Vasc Health Risk Manag 7(-): 577-84 (2011)
2011  
239
Treatment options for hypertension in high-risk patients.
[21468174] Vasc Health Risk Manag 7(-): 137-41 (2011)
2011  
240
Olmesartan/amlodipine: a review of its use in the management of hypertension.
[21490944] Vasc Health Risk Manag 7(-): 183-92 (2011)
2007  
241
Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension.
[18200799] Vasc Health Risk Manag 3(6): 783-95 (2007)
2010  
242
The 'neuroadrenergic hypothesis' in hypertension: current evidence.
[20008032] Exp Physiol 95(5): 581-6 (2010)
2005  
243
Sympatho-renal interactions in the determination of arterial pressure: role in hypertension.
[15604108] Exp Physiol 90(2): 183-7 (2005)
2005  
244
Role of leptin in obesity-related hypertension.
[16105937] Exp Physiol 90(5): 683-8 (2005)
2008  
245
A sympathetic view of the sympathetic nervous system and human blood pressure regulation.
[18326553] Exp Physiol 93(6): 715-24 (2008)
2010  
246
Redox unbalance: NADPH oxidase as therapeutic target in blood pressure control.
[20549031] Arq Bras Cardiol 94(5): 643-51, 684-93 (2010)
2007  
247
Occurrence rate and clinical predictors of hypertensive pseudocrisis in emergency room care.
[17589634] Arq Bras Cardiol 88(5): 579-84 (2007)
2007  
248
Mechanisms and treatment of resistant hypertension.
[17664996] Arq Bras Cardiol 88(6): 683-92 (2007)
2011  
249
Dutch guideline for the management of hypertensive crisis -- 2010 revision.
[21646675] Neth J Med 69(5): 248-55 (2011)
2010  
250
Hypertension in pediatric patients.
[20622277] Indian Pediatr 47(6): 473-4 (2010)
2006  
251
2007  
252
Evaluation and management of hypertension.
[17351301] Indian Pediatr 44(2): 103-21 (2007)
2004  
253
2007  
254
Genetic basis of polygenic hypertension.
[17911162] Hum Mol Genet 16 Spec No. 2(-): R195-202 (2007)
2011  
255
Hypertension in people with type 2 diabetes: Update on pharmacologic management.
[21918140] Can Fam Physician 57(9): 997-1002, e347-53 (2011)
2010  
256
Role of the kidney in the prenatal and early postnatal programming of hypertension.
[19794108] Am J Physiol Renal Physiol 298(2): F235-47 (2010)
2008  
257
Programming of hypertension: the nervous kidney.
[18463313] Am J Physiol Renal Physiol 295(1): F27-8 (2008)
2010  
258
The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis.
[20798254] Clin J Am Soc Nephrol 5(10): 1893-903 (2010)
2007  
259
Resistant hypertension: a methodological approach to diagnosis and treatment.
[17679742] Saudi J Kidney Dis Transpl 18(3): 337-45 (2007)
2011  
260
Altered neural and vascular mechanisms in hypertension.
[21615201] Physiol Res 60(3): 381-402 (2011)
2010  
261
The role of renin-angiotensin system in prothrombotic state in essential hypertension.
[19249905] Physiol Res 59(1): 13-23 (2010)
2009  
262
Renin-angiotensin-aldosterone system in the elderly: rational use of aliskiren in managing hypertension.
[19503776] Clin Interv Aging 4(-): 137-51 (2009)
2008  
263
NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities.
[18227481] Diabetes Care 31 Suppl 2(-): S170-80 (2008)
2010  
264
2011  
265
Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly.
[21878862] Pol Arch Med Wewn 121(7-8): 253-8 (2011)
2010  
266
Genetic architecture of complex traits predisposing to nephropathy: hypertension.
[20347644] Semin Nephrol 30(2): 150-63 (2010)
2011  
267
Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension.
[21339086] Curr Opin Pharmacol 11(2): 180-6 (2011)
2010  
268
Role of the adaptive immune system in hypertension.
[20167535] Curr Opin Pharmacol 10(2): 203-7 (2010)
2010  
269
Aldosterone renin ratio in patients with resistant hypertension.
[20360029] QJM 103(11): 897-9 (2010)
2008  
270
New techniques for assessing arterial stiffness.
[18358423] Diabetes Metab 34 Suppl 1(-): S21-6 (2008)
2010  
271
Hypertension and renal calcium transport.
[21170867] J Nephrol 23 Suppl 16(): S112-7 (2010)
2009  
272
Fifty years of thiazide diuretic therapy for hypertension.
[19901136] Arch Intern Med 169(20): 1851-6 (2009)
2010  
273
Excess dietary salt intake alters the excitability of central sympathetic networks.
[20434471] Physiol Behav 100(5): 519-24 (2010)
2011  
274
Current status of aggressive blood pressure control.
[21499494] World J Cardiol 3(3): 65-71 (2011)
2011  
275
Inflammation in the pathophysiology of essential hypertension.
[20437401] J Nephrol 24(1): 23-34 (2011)
2009  
276
Oral drugs for hypertensive urgencies: systematic review and meta-analysis.
[20512292] Sao Paulo Med J 127(6): 366-72 (2009)
2007  
277
Non-pharmacological management of hypertension.
[18025751] Indian J Med Sci 61(11): 616-24 (2007)
2007  
278
2007  
279
Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazide.
[17887997] Int J Clin Pract 61(12): 2093-102 (2007)
2008  
280
Organic anion transporter 3 inhibitors as potential novel antihypertensives.
[18973812] Pharmacol Res 58(5-6): 257-61 (2008)
2010  
281
Physiologic tailoring of treatment in resistant hypertension.
[21532778] Curr Cardiol Rev 6(2): 119-23 (2010)
2007  
282
Modern antihypertensive therapy: a report from the 22nd annual meeting of the American Society of Hypertension.
[18297145] Timely Top Med Cardiovasc Dis 11(-): E17 (2007)
2007  
283
New joint European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension.
[18297146] Timely Top Med Cardiovasc Dis 11(-): E18 (2007)
2007  
284
New research and new guidelines for the treatment of hypertension: a report from the 17th European Meeting on Hypertension.
[18297147] Timely Top Med Cardiovasc Dis 11(-): E19 (2007)
2005  
285
2011  
286
Vascular stiffness and increased pulse pressure in the aging cardiovascular system.
[21845218] Cardiol Res Pract 2011(-): 263585 (2011)
2011  
287
Update on diagnosis and treatment of resistant hypertension.
[21725176] Iran J Kidney Dis 5(4): 215-27 (2011)
2008  
288
Childhood hypertension: new concepts, definitions, and diagnostic evaluations.
[19377224] Iran J Kidney Dis 2(3): 123-6 (2008)
2011  
289
High-salt diet and hypertension: focus on the renin-angiotensin system.
[21071956] Kidney Blood Press Res 34(1): 1-11 (2011)
2011  
290
The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension.
[21207253] Curr Hypertens Rep 13(2): 109-15 (2011)
2010  
291
Masked hypertension: evidence of the need to treat.
[20694858] Curr Hypertens Rep 12(5): 349-55 (2010)
2009  
292
The role of the sympathetic nervous system in obesity-related hypertension.
[19442330] Curr Hypertens Rep 11(3): 206-11 (2009)
2010  
293
Novel drugs targeting hypertension revisited.
[20844362] J Cardiovasc Pharmacol 56(3): 213-4 (2010)
2010  
294
Targeting epoxides for organ damage in hypertension.
[20531214] J Cardiovasc Pharmacol 56(4): 329-35 (2010)
2010  
295
20-hydroxyeicosatetraeonic acid: a new target for the treatment of hypertension.
[20930591] J Cardiovasc Pharmacol 56(4): 336-44 (2010)
2002  
296
The sympathetic nervous system: the muse of primary hypertension.
[11986898] J Hum Hypertens 16 Suppl 1(-): S64-9 (2002)
2002  
297
Diuretics in the therapy of hypertension.
[11986901] J Hum Hypertens 16 Suppl 1(-): S78-83 (2002)
2002  
298
Angiotensin II receptor antagonists role in arterial hypertension.
[11986904] J Hum Hypertens 16 Suppl 1(-): S93-9 (2002)
2002  
299
Diuretics in the treatment of patients who present congestive heart failure and hypertension.
[11986906] J Hum Hypertens 16 Suppl 1(-): S104-13 (2002)
2002  
300
Update on the use of calcium antagonists on hypertension.
[11986907] J Hum Hypertens 16 Suppl 1(-): S114-7 (2002)
2002  
301
Sympatholytic therapy in primary hypertension: a user friendly role for the future.
[11986908] J Hum Hypertens 16 Suppl 1(-): S118-23 (2002)
2002  
302
Is aldosterone the missing link in refractory hypertension?: aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity.
[11896503] J Hum Hypertens 16(3): 153-8 (2002)
2002  
303
Isolated systolic hypertension: a new challenge in medicine.
[11986893] J Hum Hypertens 16 Suppl 1(-): S44-7 (2002)
2002  
304
Doxazosin, an inferior antihypertensive agent?
[12037690] J Hum Hypertens 16(6): 375-7 (2002)
2010  
305
The epidemiology and management of severe hypertension.
[19440209] J Hum Hypertens 24(1): 9-18 (2010)
2010  
306
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension.
[20226958] Prog Cardiovasc Dis 52(5): 401-9 (2010)
2008  
307
Electrocardiographic left ventricular hypertrophy with strain pattern: prevalence, mechanisms and prognostic implications.
[18320088] Cardiovasc J Afr 19(1): 39-45 (2008)
2009  
308
Characterization and treatment of resistant hypertension.
[19863864] Curr Cardiol Rep 11(6): 407-13 (2009)
2010  
309
Antihypertensive agents in hemodialysis patients: a current perspective.
[20374548] Semin Dial 23(3): 290-7 (2010)
2008  
310
Are statins effective for simultaneously treating dyslipidemias and hypertension?
[17662294] Atherosclerosis 196(1): 1-8 (2008)
2009  
311
Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment--a review.
[19327149] Cardiovasc Diabetol 8(-): 18 (2009)
2010  
312
Optimal management of hypertension in elderly patients.
[21949630] Integr Blood Press Control 3(-): 145-53 (2010)
2011  
313
Hypertension in chronic kidney disease: navigating the evidence.
[21747971] Int J Hypertens 2011(-): 132405 (2011)
2011  
314
Prevalence, risk factors, and management of prehypertension.
[22121474] Int J Hypertens 2011(-): 605359 (2011)
2010  
315
PPARs in the Renal Regulation of Systemic Blood Pressure.
[20613959] PPAR Res 2010(-): 698730 (2010)
2010  
316
Arterial baroreceptors in the management of systemic hypertension.
[20037502] Med Sci Monit 16(1): RA1-8 (2010)
2008  
317
Heat stress and baroreflex regulation of blood pressure.
[18981943] Med Sci Sports Exerc 40(12): 2063-70 (2008)
2009  
318
Collecting Duct Renin: A major player in Angiotensin II-dependent Hypertension.
[20046983] J Am Soc Hypertens 3(2): 96-104 (2009)
2011  
319
Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension.
[21755262] Braz J Med Biol Res 44(9): 871-6 (2011)
2010  
320
Control of elevated blood pressure in acute intracerebral hemorrhage.
[21173835] F1000 Med Rep 2(-): 75 (2010)
2010  
321
Recent advances in the management of hypertension.
[20948867] F1000 Med Rep 2(-): - (2010)
2009  
322
Cellular mediators of renal vascular dysfunction in hypertension.
[19225145] Am J Physiol Regul Integr Comp Physiol 296(4): R1001-18 (2009)
2009  
323
The pathophysiology of hypertension in systemic lupus erythematosus.
[19158408] Am J Physiol Regul Integr Comp Physiol 296(4): R1258-67 (2009)
2010  
324
Diagnosis of secondary hypertension: an age-based approach.
[21166367] Am Fam Physician 82(12): 1471-8 (2010)
2010  
325
Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation.
[20153824] Biochim Biophys Acta 1802(12): 1259-67 (2010)
2010  
326
Regulation of GPCR signaling in hypertension.
[20060896] Biochim Biophys Acta 1802(12): 1268-75 (2010)
2010  
327
T cells and blood vessels: costimulation turns up the pressure.
[21126974] Circulation 122(24): 2495-8 (2010)
2011  
328
Hypertension, dietary salt intake, and the role of the thiazide-sensitive sodium chloride transporter NCCT.
[21167012] Cardiovasc Ther 29(1): 68-76 (2011)
2010  
329
Prehypertension: the rationale for early drug therapy.
[20553286] Cardiovasc Ther 28(6): 339-43 (2010)
2010  
330
Overnight rostral fluid shift and obstructive sleep apnea in treatment resistant hypertension: connecting the dots clarifies the picture.
[21059995] Hypertension 56(6): 1040-1 (2010)
PMC   
331
Effect of sphingosine kinase 1 inhibition on blood pressure.
[23109673] FASEB J 27(2):656-64 (2013)
PMC   
332
Aldosterone synthase inhibitors in hypertension: current status and future possibilities.
[24570839] JRSM Cardiovasc Dis 3():2048004014522440 (2014)
PMC   
333
Cost-effectiveness of secondary screening modalities for hypertension.
[23263535] Blood Press Monit 18(1):1-7 (2013)
PMC   
334
American Heart Association Scientific Sessions 2013: Agents for Hypertension, Heart Failure, and Acute Myocardial Infarction.
[24672217] P T 39(1):65-7 (2014)
PMC   
335
Diabetes: treating hypertension.
[22456232] Clin Evid (Online) 2012(): (2012)
PMC   
336
Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?
[24711696] Clin Interv Aging 9():459-75 (2014)
PMC   
337
Hypoxia stress test reveals exaggerated cardiovascular effects in hypertensive rats after exposure to the air pollutant acrolein.
[23335627] Toxicol Sci 132(2):467-77 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia